Resistance mechanisms in clinical isolates of Candida albicans

Theodore C White1, Scott Holleman, Francis Dy

  • 1Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington 98109-1651, USA. tedwhite@u.washington.edu

Insights

Mechanisms of azole antifungal resistance in Candida albicans are diverse. Known resistance genes like ERG11 and efflux pumps CDR1/CDR2 are not always linked to resistance in clinical isolates, suggesting unknown factors contribute.

Area of Science:

  • Mycology
  • Antimicrobial Resistance

Background:

  • Azole antifungals are crucial for treating Candida albicans infections.
  • Mechanisms of azole resistance, including ERG11 mutations and efflux pump overexpression (CDR1, CDR2, MDR1), are known from matched isolates.
  • Unmatched clinical isolates present a challenge in understanding resistance mechanisms.

Purpose of the Study:

  • To investigate known molecular mechanisms of azole antifungal resistance in a collection of unmatched Candida albicans clinical isolates.
  • To determine the correlation between specific gene alterations and azole resistance phenotypes.
  • To identify potential novel resistance mechanisms in clinical settings.

Main Methods:

  • Analysis of a collection of unmatched Candida albicans clinical isolates, with approximately half being azole-resistant.
  • Standard methods including Northern blotting to assess gene expression (CDR1, CDR2, MDR1, FLU1).
  • Restriction fragment length polymorphism (RFLP) analysis to detect specific ERG11 point mutations (D116E, E266D).

Main Results:

  • Extensive cross-resistance observed among fluconazole, clotrimazole, itraconazole, and ketoconazole.
  • Overexpression of CDR1 and CDR2 correlated with resistance, suggesting coregulation.
  • MDR1 overexpression was infrequent; FLU1 overexpression did not correlate with resistance. ERG11 overexpression was not observed.
  • Common ERG11 mutations (D116E, E266D) were frequent but not reliably associated with resistance in this cohort.

Conclusions:

  • Known resistance mechanisms identified in matched isolates are insufficient to explain azole resistance in diverse, unmatched clinical isolates.
  • The study highlights the heterogeneity of azole resistance mechanisms in Candida albicans.
  • Additional, yet undiscovered, mechanisms likely contribute to azole resistance in clinical settings.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...